Personalis (PSNL) Files Patent Infringement Lawsuit Against Foresight Diagnostics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics
August 2, 2022 4:10 PM EDTMENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it filed a lawsuit against Foresight Diagnostics Inc. for infringement of Personalis U.S. Patent Nos. 10,450,611, 11,299,783, and 11,384,394. These patents are part of Personalis intellectual property portfolio in the field of whole genome-enabled, tumor-informed molecular residual disease (MRD) testing.
Personalis patent portfolio protects its pioneering work in whole genome sequencing to identify mutations that indicate the continued presence or recurrence of cancer with part-per-million sensitivity. Personalis is seeking both injunctive relief and monetary damages... More



